We use cookies to ensure that we give you the best experience on our website.
17
Jun
Elucid Mhealth Set To Revolutionise Healthcare Technology After £49.5k Investment

Business Finance Solutions has awarded innovative healthcare tech company e Lucid m Health a £49,500 investment from the £3m North West Fund for Micro Loans to bring their patented series of medical monitoring products to market in the UK and overseas.

e Lucid m Health, who are based at Manchester Science Partnership, is a full service provider of software, hardware, medical devices and cloud support. They will be using the funds to continue the development of a range of remote dispensing and monitoring devices, which will address the serious £350m problem of non-compliance. All of the core products are connected to smartphones using Bluetooth to track when patients dispense their medication, giving health professionals accurate data to enable them to deliver better patient centric care.

One of the first inventions is eBottle, an intelligent remote dispensing system for the safe delivery of tablets which has multiple applications across highly toxic or time sensitive drug regimes. The technology platform is specifically designed to link into other diagnostic and screening devices such as blood glucose, non-contact thermometers, oximeters and blood pressure monitors. The company is also in the process of creating new devices for patient groups such as diabetes, schizophrenia, mental health and pain management via its on-going work with the NHS.

e Lucid Directors, founders Graham Howieson and Dr Farid Khan are both specialists in the medical sector with expertise in medical packaging and biopharma and diagnostics respectively. Graham is also a Director of GP Solutions (UK) Ltd.

Graham says: “One of the biggest issues in healthcare today is to improve the efficiency and effectiveness of patient facing care and digital technology can play a major part in transforming the delivery of accurate medication and wellness solutions. To achieve this we have to increase the level of patient adherence across all walks of life, especially supporting vulnerable patients. This is a costly issue, which needs to be addressed and to quote the US Surgeon General, Evelyn Kopp “Drugs don’t work in patients that don’t take them”. 

“The work being performed at e Lucid is ground-breaking and could have numerous applications in general health and acute care. Our combined platform solutions give health professionals the tools and the technology to save lives and money as well as empowering patients to live a happy and healthy life. Thanks to the loan from the Micro Fund, we are now able to move forward our development and employ new staff to fulfil the relationships we have in place with some of the largest healthcare companies in the world and with the NHS here in the UK.”